Director Acquires $5 Million in Common Stock at IPO Price Following Company's Public Offering

summarizeSummary

A director of Avalyn Pharma Inc. acquired over $5 million in common stock at the IPO price, while also seeing a significant conversion of preferred stock to common stock, signaling strong insider confidence post-IPO.

check_boxKey Events

• Director's Open Market Purchase

  Director Jill Carroll's affiliated entity purchased 277,778 shares of common stock for $5,000,004 at an average price of $18.00 per share on May 1, 2026. This purchase occurred at the company's IPO price, which is significantly below the current trading price of $29.55.

• Automatic Preferred Stock Conversion

  On the same date, preferred stock held by the director's affiliated entity automatically converted into 1,908,784 shares of common stock as part of the IPO, increasing the total common stock holdings.

• Significant Post-IPO Holdings

  Following these transactions, the director's affiliated entity holds a substantial indirect stake in Avalyn Pharma, aligning their interests with common shareholders after the company's public offering.

auto_awesomeAnalysis

This Form 4 filing indicates a significant vote of confidence from Director Jill Carroll following Avalyn Pharma's recent initial public offering. The director's affiliated entity made an open market purchase of over $5 million in common stock at the IPO price of $18.00 per share. This purchase is particularly notable as the stock is currently trading significantly higher at $29.55, suggesting strong conviction in the company's valuation and future prospects immediately post-IPO. Additionally, a substantial amount of preferred stock held by the director's affiliated entity automatically converted into common stock as part of the IPO, further increasing their alignment with common shareholders. This transaction provides a positive signal to the market regarding insider belief in the company's trajectory after its public debut.